A head-to-head trial compares cost-effectiveness of pembrolizumab plus chemotherapy in metastatic lung cancer, suggesting real-world data indicates lower effectiveness than trial results.
Pembrolizumab plus platinum therapy is unlikely to be cost-effective for mNSCLC. The higher ICER with RWE compared to RCT data suggests that trial-based outcomes may overestimate effectiveness in routine practice. These findings highlight the importance of incorporating RWE into post-approval reassessment for high-cost oncology therapies.
No takes yet. Share an insight, caveat, or question.
Teppala et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: